Increased toxicity of a trinuclear Pt-compound in a human squamous carcinoma cell line by polyamine depletion

Cancer Cell International

Volumn 12, Issue , 2012, Pages

  Kjellström, Johan ^a,b   Oredsson, Stina M ^c   Wennerberg, Johan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Ferring Pharmaceuticals AS   (Denmark)

^c LUND UNIVERSITY   (Sweden)

Author keywords

difluoromethylornithine; BBR3464; Cisplatin; Head and neck carcinoma; Isobologram; N1,N11 diethylnorspermine; Polyamines

Indexed keywords

CISPLATIN; EFLORNITHINE; N1,N11 DIETHYLNORSPERMINE; POLYAMINE; SPERMIDINE; SPERMINE; TRIPLATIN TETRANITRATE;

ARTICLE; CONTROLLED STUDY; HEAD AND NECK TUMOR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; SQUAMOUS CELL CARCINOMA;

EID: 84861425796     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-12-20     Document Type: Article

References (48)

1. Brabec V, Kasparkova J, Vrana O, Novakova O, Cox JW, Qu Y, Farrell N. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Biochemistry 1999, 38:6781-6790. 10.1021/bi990124s, 10346899.
2. Manzotti C, Pratesi G, Menta E, Di Domenico R, Cavalletti E, Fiebig HH, Kelland LR, Farrell N, Polizzi D, Supino R, Pezzoni G, Zunino F. BBR3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res 2000, 6:2626-2634.
3. Riccardi A, Ferlini C, Meco D, Mastrangelo R, Scambia G, Riccardi R. Antitumour activity of oxaliplatin in neuroblastoma cell lines. Eur J Cancer 1999, 35:86-90. 10.1016/S0959-8049(98)00342-6, 10211093.
4. Orlandi L, Colella G, Bearzatto A, Abolafio G, Manzotti C, Daidone MG, Zaffaroni N. Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: interference with cell cycle progression and induction of apoptosis. Eur J Cancer 2001, 37:649-659. 10.1016/S0959-8049(00)00445-7, 11290441.
5. Perego P, Caserini C, Gatti L, Carenini N, Romanelli S, Supino R, Colangelo D, Viano I, Leone R, Spinelli S, Pezzoni G, Manzotti C, Farrell N, Zunino F. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol 1999, 55:528-534.
6. Perego P, Gatti L, Caserini C, Supino R, Colangelo D, Leone R, Spinelli S, Farrell N, Zunino F. The cellular basis of the efficacy of the trinuclear platinum complex BBR3464 against cisplatin-resistant cells. J Inorg Biochem 1999, 77:59-64. 10.1016/S0162-0134(99)00142-7, 10626355.
7. Servidei T, Ferlini C, Riccardi A, Meco D, Scambia G, Segni G, Manzotti C, Riccardi R. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur J Cancer 2001, 37:930-938. 10.1016/S0959-8049(01)00061-2, 11313183.
8. Pratesi G, Perego P, Polizzi D, Righetti SC, Supino R, Caserini C, Manzotti C, Giuliani FC, Pezzoni G, Tognella S, Spinelli S, Farrell N, Zunino F. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer 1999, 80:1912-1919. 10.1038/sj.bjc.6690620, 2363141, 10471039.
9. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000, 87:227-253. 10.1016/S0163-7258(00)00086-3, 11008002.
10. Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 2002, 87:825-833. 10.1038/sj.bjc.6600540, 2376170, 12373594.
11. Gourley C, Cassidy J, Edwards C, Samuel L, Bisset D, Camboni G, Young A, Boyle D, Jodrell D. A phase I study of the trinuclear platinum compound, BBR3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer Chemother Pharmacol 2004, 53:95-101. 10.1007/s00280-003-0721-x, 14605864.
12. Cohen S. A Guide to the Polyamines 1998, Oxford University Press Inc, Oxford.
13. Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981, 19:1-20. 10.1111/j.1432-0436.1981.tb01123.x, 6173280.
14. Porter CW, Bergeron RJ. Enzyme regulation as an approach to interference with polyamine biosynthesis-an alternative to enzyme inhibition. Adv Enzyme Regul 1988, 27:57-79.
15. Porter CW, Ganis B, Libby PR, Bergeron RJ. Correlations between polyamine analogue-induced increases in spermidine/spermine N1-acetyltransferase activity, polyamine pool depletion, and growth inhibition in human melanoma cell lines. Cancer Res 1991, 51:3715-3720.
16. Seiler N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 2. Structural analogues and derivatives. Curr Drug Targets 2003, 4:565-585. 10.2174/1389450033490876, 14535655.
17. Alm K, Berntsson PS, Kramer DL, Porter CW, Oredsson S. Treatment of cells with the polyamine analog N1, N11-diethylorspermine retards S phase progression within one cell cycle. Eur J Biochem 2000, 267:4157-4164. 10.1046/j.1432-1327.2000.01460.x, 10866819.
18. Hegardt C, Johannsson OT, Oredsson S. Rapid caspase-dependent cell death in cultured human breast cancer cells induced by the polyamine N1, N11-diethylorspermine. Eur J Biochem 2002, 269:1033-1039. 10.1046/j.0014-2956.2001.02744.x, 11846806.
19. Seiler N, Delcros JG, Moulinoux JP. Polyamine transport in mammalian cells. An update. Int J Biochem Cell Biol 1996, 28:843-861. 10.1016/1357-2725(96)00021-0, 8811834.
20. Alhonen-Hongisto L, Seppanen P, Janne J. Intracellular putrescine and spermidine deprivation induces increased uptake of the natural polyamines and methylglyoxal bis(guanylhydrazone). Biochem J 1980, 192:941-945. 1162421, 6786285.
21. Persson L, Holm I, Ask A, Heby O. Curative effect of DL-2-difluoromethylornithine on mice bearing mutant L1210 leukemia cells deficient in polyamine uptake. Cancer Res 1988, 48:4807-4811.
22. Allen ED, Natale RB. Effect of alpha-difluoromethylornithine alone and in combination with doxorubicin hydrochloride, cis-diamminedichloroplatinum (II), and vinblastine sulfate on the growth of P3J cells in vitro. Cancer Res 1986, 46:3550-3555.
23. Chang BK, Black O, Gutman R. Inhibition of growth of human or hamster pancreatic cancer cell lines by alpha-difluoromethylornithine alone and combined with cis-diamminedichloroplatinum (II). Cancer Res 1984, 44:5100-5104.
24. Chang BK, Gutman R, Chou TC. Schedule-dependent interaction of alpha-difluoromethylornithine and cis-diamminedichloroplatinum(II) against human and hamster pancreatic cancer cell lines. Cancer Res 1987, 47:2247-2250.
25. Hawthorne TR, Austin JK. Synergism of the polyamine analogue, N1, N11-bisethylnorspermine with cis-diaminedichloroplatinum (II) against murine neoplastic cell lines in vitro and in vivo. Cancer Lett 1986, 99:99-107.
26. Kurihara H, Matsuzaki S, Tamura M, Sugimoto H, Tsukahara T, Yamazaki H. alpha-Difluoromethylornithine increases the anti-tumor effect of cis-diamminedichloroplatinum in G-XII rat glioma. Neurol Med Chir (Tokyo) 1995, 35:215-220.
27. Marverti G, Piccinini G, Ghiaroni S, Barbieri D, Quaglino D, Moruzzi MS. N1, N12-bis(ethyl)spermine effect on growth of cis-diamminedichloroplatinum (II)-sensitive and -resistant human ovarian-carcinoma cell lines. Int J Cancer 1998, 78:33-40. 10.1002/(SICI)1097-0215(19980925)78:1<33::AID-IJC7>3.0.CO;2-Y, 9724091.
28. Oredsson SM, Deen DF, Marton LJ. Decreased cytotoxicity of cis-diamminedichloroplatinum (II) by alpha-difluoromethylornithine depletion of polyamines in 9 L rat brain tumor cells in vitro. Cancer Res 1982, 42:1296-1299.
29. Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, Dal Bo L, Tinelli S, Colangelo D, Leone R, Apostoli P, Lombardi L, Beggiolin G, Piazzoni L, Zunino F. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer 2003, 105:617-624. 10.1002/ijc.11140, 12740909.
30. Riccardi A, Meco D, Ferlini C, Servidei T, Carelli G, Segni G, Manzotti C, Riccardi R. In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR3464 in neuroblastoma. Cancer Chemother Pharmacol 2001, 47:498-504. 10.1007/s002800000264, 11459202.
31. Roberts JD, Peroutka J, Farrell N. Cellular pharmacology of polynuclear platinum anti-cancer agents. J Inorg Biochem 1999, 77:51-57. 10.1016/S0162-0134(99)00147-6, 10626354.
32. Gerner EW, Meyskens FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004, 4:781-792. 10.1038/nrc1454, 15510159.
33. Basu HS, Feuerstein BG, Deen DF, Lubich WP, Bergeron RJ, Samejima K, Marton LJ. Correlation between the effects of polyamine analogues on DNA conformation and cell growth. Cancer Res 1989, 49:5591-5597.
34. Bergeron RJ, Hawthorne TR, Vinson JR, Beck DE, Ingeno MJ. Role of the methylene backbone in the antiproliferative activity of polyamine analogues on L1210 cells. Cancer Res 1989, 49:2959-2964.
35. Alhonen L, Karppinen A, Uusi-Oukari M, Vujcic S, Korhonen VP, Halmekyto M, Kramer DL, Hines R, Janne J, Porter CW. Correlation of polyamine and growth responses to N1, N11-diethylnorspermine in primary fetal fibroblasts derived from transgenic mice overexpressing spermidine/spermine N1-acetyltransferase. J Biol Chem 1998, 273:1964-1969. 10.1074/jbc.273.4.1964, 9442032.
36. Chang BK, Liang Y, Miller DW, Bergeron RJ, Porter CW, Wang G. Effects of diethyl spermine analogues in human bladder cancer cell lines in culture. J Urol 1993, 150:1293-1297.
37. Hunter KJ, Deen DF, Pellarin M, Marton LJ. Effect of alpha-difluoromethylornithine on 1,3-bis(2-chloroethyl)-1-nitrosourea and cis-diamminedichloroplatinum(II) cytotoxicity, DNA interstrand cross-linking, and growth in human brain tumor cell lines in vitro. Cancer Res 1990, 50:2769-2772.
38. Marton LJ. Effects of treatment with DNA-directed cancer chemotherapeutic agents after polyamine depletion. Pharmacol Ther 1987, 32:183-190. 10.1016/0163-7258(87)90058-1, 3110798.
39. Mitchell JL, Simkus CL, Thane TK, Tokarz P, Bonar MM, Frydman B, Valasinas AL, Reddy VK, Marton LJ. Antizyme induction mediates feedback limitation of the incorporation of specific polyamine analogues in tissue culture. Biochem J 2004, 384:271-279. 10.1042/BJ20040972, 1134110, 15315476.
40. Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005, 53:13-23. 10.1016/j.critrevonc.2004.09.007, 15607932.
41. Gosland MP, Gillespie MN, Tsuboi CP, Tofiq S, Olson JW, Crooks PA, Aziz SM. Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine. Cancer Chemother Pharmacol 1996, 37:593-600. 10.1007/s002800050434, 8612315.
42. Seiler N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors. Curr Drug Targ 2003, 4:537-564.
43. Raul F. Revival of 2-(difluoromethyl)ornithine (DFMO), an inhibitor of polyamine biosynthesis, as a cancer chemopreventive agent. Biochem Soc Trans 2007, 35:353-355.
44. Gerner EW, Meyskens FL, Goldschmid S, Lance P, Pelot D. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. Amino Acids 2007, 33:189-195. 10.1007/s00726-007-0515-2, 17396214.
45. Yamatodani T, Ekblad L, Kjellén E, Johnsson A, Mineta H, Wennerberg J. Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol 2009, 135:395-402. 10.1007/s00432-008-0475-2, 18813952.
46. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 1987, 47:943-946.
47. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992, 50:604-610. 10.1002/ijc.2910500420, 1537625.
48. Seiler N, Knödgen B. Determination of poly-amines and related compounds by reverse-phase high-performance liquid chromatography: improved separation systems. J Chromatogr Biomed Appl 1985, 339:45-57.